A 77-year-old man with a history of MI is started on dual antiplatelet therapy (aspirin + clopidogrel) and also takes omeprazole. His cardiologist questions this combination. What is the clinical concern?
-
A
Omeprazole increases clopidogrel bioavailability, causing bleeding risk
-
B
Omeprazole inhibits CYP2C19 and may reduce clopidogrel's antiplatelet effect
-
C
Aspirin blocks omeprazole's gastroprotective effect
-
D
The combination causes QT prolongation